The esophageal cancer drug market in India will grow from $16 million in 2009 to $36 million in 2014, says a research firm.
According to Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, this growth will be fuelled by improved access to medical care, a growing drug-treated population and a rising number of higher-income, brand-conscious esophageal cancer patients driving the demand for more efficacious drugs.
The new emerging markets report -- Esophageal Cancer in India -- finds that the uptake of high-price targeted therapies will increase and will offset competition from less-expensive Indian brands/generics.
“The use of targeted therapies like Merck KGaA’s Erbitux and Roche’s Herceptin to treat esophageal cancer in India will increase as more results from clinical studies become available during our 2009-2014 forecast period,” stated Decision Resources’ Vice President of Emerging Markets Kate Hohenberg.
“According to surveyed Indian oncologists, however, an off-label market for these therapies -- which are approved for other cancers in India -- already exists. Most importantly neither of these drugs competes with a generic in India,” he added.
The report also finds that treatment modalities for esophageal cancer are generally similar in the four key regions of India (Delhi, Mumbai, Bangalore/Chennai and Kolkata/Hyderabad/Jaipur/Lucknow).
Oncologists from Bangalore/Chennai, however, are more conservative about treating recurrent esophageal cancer with chemotherapy. In contrast to their colleagues in the other major cities, they tend to perform more surgery and radiation to ease the symptoms.